Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, and GATHER1 Study: Results From a Post-Hoc Analysis of Nascent Geographic Atrophy

Peter K. Kaiser, MD FASRS

Video
Published 2021

Related

Use of Ellipsoid Zone Analysis As an Efficacy Endpoint in Clinical Trials for Geographic Atrophy
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2023
Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy: An Anchored Matching-Adjusted Indirect Comparison of the Phase 3 Trials
Paul Hahn, MD, PhD, FASRS
Annual Meeting Talks
2023
Machine and Deep Learning (AI) Algorithms for GA Identification and Prediction of Progression to GA from Intermediate AMD: The Future of Dry AMD Management
Eleonora Lad, MD, PhD
Updates from the Field
2023

Category: AMD-Non-Neovascular

See more